Biocon has announced the commercial launch of Yesafili (aflibercept-jbvf) in the US. Yesafili, a Vascular Endothelial Growth Factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product Eylea (aflibercept) 2 mg. The product was approved previously and granted interchangeable designation by the US Food and Drug Administration (FDA) in May 2024, allowing substitution at the pharmacy level in accordance with state laws.

Shreehas Tambe, Chief Executive Officer (CEO) and Managing Director (MD), Biocon, said, “The launch of Yesafili in the US marks an important step in expanding the global availability of biosimilar Aflibercept 2 mg for patients with eye conditions. This milestone further strengthens our presence in ophthalmology and builds on our FDA approval as one of the first interchangeable biosimilars to Eylea 2 mg, advancing access to life-changing medicines for patients around the world.”

An estimated 19.8 million Americans are living with Age-related Macular Degeneration (AMD) while US sales of aflibercept reached approximately USD 5.89 billion in 2023, underscoring the growing need for effective treatment options.